Table of Contents
Journal of Neurodegenerative Diseases
Volume 2016, Article ID 5780809, 8 pages
http://dx.doi.org/10.1155/2016/5780809
Review Article

Risk of Parkinson’s Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies

Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, SAS Nagar, Punjab 160062, India

Received 30 March 2016; Accepted 21 June 2016

Academic Editor: Eng King Tan

Copyright © 2016 Amarnath Mullapudi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. M. de Lau and M. M. Breteler, “Epidemiology of Parkinson's disease,” The Lancet Neurology, vol. 5, no. 6, pp. 525–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. X.-X. Dong, Y. Wang, and Z.-H. Qin, “Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases,” Acta Pharmacologica Sinica, vol. 30, no. 4, pp. 379–387, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Surmeier, J. N. Guzman, J. Sanchez-Padilla, and J. A. Goldberg, “The origins of oxidant stress in parkinson's disease and therapeutic strategies,” Antioxidants and Redox Signaling, vol. 14, no. 7, pp. 1289–1301, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Rees, R. Stowe, S. Patel et al., “Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials,” Cochrane Database of Systematic Reviews, vol. 9, no. 11, Article ID CD008535, 2011. View at Google Scholar · View at Scopus
  5. Y.-C. Lee, C.-H. Lin, R.-M. Wu, J.-W. Lin, C.-H. Chang, and M.-S. Lai, “Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study,” PLoS ONE, vol. 9, no. 6, Article ID e98961, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Pasternak, H. Svanström, N. M. Nielsen, L. Fugger, M. Melbye, and A. Hviid, “Use of calcium channel blockers and Parkinson's disease,” American Journal of Epidemiology, vol. 175, no. 7, pp. 627–635, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. K. C. Simon, X. Gao, H. Chen, M. A. Schwarzschild, and A. Ascherio, “Calcium channel blocker use and risk of Parkinson's disease,” Movement Disorders, vol. 25, no. 12, pp. 1818–1822, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. D. Louis, J. Benito-León, and F. Bermejo-Pareja, “Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES),” Neuroepidemiology, vol. 33, no. 3, pp. 286–292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Becker, S. S. Jick, and C. R. Meier, “Use of antihypertensives and the risk of Parkinson disease,” Neurology, vol. 70, no. 16, part 2, pp. 1438–1444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Ritz, S. L. Rhodes, L. Qian, E. Schernhammer, J. H. Olsen, and S. Friis, “L-type calcium channel blockers and Parkinson disease in Denmark,” Annals of Neurology, vol. 67, no. 5, pp. 600–606, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. G. N. Ton, S. R. Heckbert, W. T. Longstreth Jr. et al., “Calcium channel blockers and β-blockers in relation to Parkinson's disease,” Parkinsonism and Related Disorders, vol. 13, no. 3, pp. 165–169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. G. A. Wells, B. Shea, D. O'Connell et al., “The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses,” 2011, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
  13. S. Rabe-Hesketh and B. Everitt, Handbook of Statistical Analyses Using Stata, CRC Press, Boca Raton, Fla, USA, 2000.
  14. J. P. Higgins and S. Green, “Cochrane handbook for systematic reviews of interventions,” 2008, http://handbook.cochrane.org/.
  15. M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” The British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Duval and R. Tweedie, “A nonparametric ‘trim and fill’ method of accounting for publication bias in meta-analysis,” Journal of the American Statistical Association, vol. 95, no. 449, pp. 89–98, 2000. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  17. D. Dickson and R. O. Weller, Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, John Wiley & Sons, New York, NY, USA, 2011.
  18. J. H. Weiss, D. M. Hartley, J. Y. Koh, and D. W. Choi, “The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity,” Science, vol. 247, no. 4949, pp. 1474–1477, 1990. View at Publisher · View at Google Scholar · View at Scopus
  19. D. J. Surmeier, “Calcium, ageing, and neuronal vulnerability in Parkinson's disease,” The Lancet Neurology, vol. 6, no. 10, pp. 933–938, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. D. J. Surmeier, J. N. Guzman, J. Sanchez-Padilla, and P. T. Schumacker, “The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease,” Neuroscience, vol. 198, pp. 221–231, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. A. Haaxma, B. R. Bloem, G. F. Borm et al., “Gender differences in Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 8, pp. 819–824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Suzuki, M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, V. Esteban, and J. Egido, “Inflammation and angiotensin II,” International Journal of Biochemistry & Cell Biology, vol. 35, no. 6, pp. 881–900, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Ge and N. M. Barnes, “Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders,” European Journal of Pharmacology, vol. 297, no. 3, pp. 299–306, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Obata, S. Takahashi, Y. Kashiwagi, and S. Kubota, “Protective effect of captopril and enaraprilat, angiotensin-converting enzyme inhibitors, on para-nonylphenol-induced ·OH generation and dopamine efflux in rat striatum,” Toxicology, vol. 250, no. 2-3, pp. 96–99, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Rey, A. Lopez-Real, S. Sanchez-Iglesias, A. Muñoz, R. Soto-Otero, and J. L. Labandeira-Garcia, “Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons,” Neurobiology of Aging, vol. 28, no. 4, pp. 555–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. K. S. Rommelfanger and D. Weinshenker, “Norepinephrine: the redheaded stepchild of Parkinson's disease,” Biochemical Pharmacology, vol. 74, no. 2, pp. 177–190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Gaspar, C. Duyckaerts, C. Alvarez, F. Javoy-Agid, and B. Berger, “Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease,” Annals of Neurology, vol. 30, no. 3, pp. 365–374, 1991. View at Publisher · View at Google Scholar · View at Scopus